News Image

Collegium Reports Record Third Quarter 2024 Financial Results

Provided By GlobeNewswire

Last update: Nov 7, 2024

– Generated Record Q3’24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca® Revenue of $53.2 Million and Record Xtampza® ER Revenue of $49.5 Million –

Read more at globenewswire.com

COLLEGIUM PHARMACEUTICAL INC

NASDAQ:COLL (3/7/2025, 8:15:47 PM)

After market: 28.91 0 (0%)

28.91

-0.89 (-2.99%)



Find more stocks in the Stock Screener

Follow ChartMill for more